Question 1

What commonly slows or complicates cardio-oncology echo surveillance in routine practice?

Accepted Answer

Surveillance is often delayed by off-site echo lab scheduling, sonographer availability, and misalignment between oncology visits and imaging appointments, leading to fragmented and episodic cardiac assessment.

Question 2

How often is LVEF monitored during HER2-targeted therapy (e.g., trastuzumab)?

Accepted Answer

Common practice includes a baseline echocardiogram followed by repeat LVEF assessment approximately every 3 months during HER2-targeted therapy, with adjustments based on risk and prior findings.

Question 3

How is cardiac function monitored during anthracycline therapy (e.g., doxorubicin)?

Accepted Answer

Anthracycline monitoring is typically risk- and dose-dependent, often including baseline imaging and follow-up studies at defined cumulative dose thresholds or when clinical risk factors are present.

Question 4

Can cardiac monitoring be performed within the oncology or cardiology clinic?

Accepted Answer

Yes. Several care models support in-clinic image acquisition with cardiology oversight. Sonus is developing an autonomous, in-clinic ultrasound approach designed to support this workflow without requiring a dedicated sonographer at the point of care.

Question 5

What is the Sonus Patch?

Accepted Answer

The Sonus patch is an in-clinic, autonomous echocardiography device under development, designed to support repeatable cardiac assessment during routine visits in cardiology and oncology settings.

Question 6

How is the Sonus patch intended to function in a clinical workflow?

Accepted Answer

The system is designed for rapid, in-clinic image acquisition by clinic staff, with cardiac images transmitted for remote cardiologist review and interpretation, aligning cardiac assessment more closely with oncology or cardiology visit timing.

Question 7

Does the Sonus system use AI, and what results are available at the point of care?

Accepted Answer

The platform is being developed to incorporate image capture and recording and AI-based analysis to support immediate estimation of left ventricular ejection fraction (LVEF), with cardiologist oversight intended for confirmation and clinical decision-making.

Question 8

What is the difference between LVEF and GLS in cardio-oncology monitoring?

Accepted Answer

LVEF remains the primary metric used for clinical decision-making in cardio-oncology and is the only cardiac function measure explicitly referenced in FDA labeling and drug manufacturer guidance, while global longitudinal strain (GLS) is used in some programs as an adjunct to identify earlier functional changes in selected patients.

Question 9

What data would a clinical partner site evaluate in an early pilot or feasibility study?

Accepted Answer

Early evaluations typically focus on agreement with standard echocardiography for LVEF, scan usability rates, time to results, and potential impact on care coordination or treatment delays.

Autonomous Ultrasound for In-clinic Cardiac Function Monitoring

Designed to support repeatable, operator-independent cardiac assessment, including ejection fraction (LVEF) measurement, for cardiology workflows and cardio-oncology monitoring during potentially cardiotoxic therapy.

* In development. Not FDA cleared. Now enrolling the first cohort of clinical partner sites.

Care Coordination is Challenging at the Cardio-oncology Handoff

Guidelines call for baseline EF and repeat echo every 3 months for cardiotoxic therapies, but adherence is low.

Off-site echo labs run on separate schedules and limited capacity, creating multi-day to multi-week delays.

When LVEF results aren’t available on time, chemo decisions can be delayed or made with incomplete information.

In cardio-oncology programs, surveillance echocardiography for cardiotoxic therapies (e.g., anti-HER2 therapy or anthracyclines) can be difficult to operationalize, contributing to delays, missed monitoring windows and professional liability.

Simple Setup, Repeatable Cardiac Monitoring

Bring repeatable cardiac function assessment closer to the patient. The AI-enabled Sonus patch is being developed to support operator-independent, in-clinic ultrasound assessment, including ejection fraction, without the scheduling and staffing constraints of traditional echo.

In-clinic and on-demand LVEF monitoring

Designed for Cardiology and Oncology Teams

Consistent trending across cycles and visit

Less scheduling friction and better adherence

Join the First Clinical Partner Cohort

We’re inviting a limited number of cardiology and oncology sites to help define clinic-based cardiac monitoring workflows, including repeatable ejection fraction assessment, as the Sonus Patch progresses through clinical testing.

Using the patch in the echo lab

Collaboration with oncology clinics

Early pilot interest

Information and updates

Sonus products described on this page are under development and are not FDA cleared or approved for clinical use at the moment. This content is intended for informational and collaboration-seeking purposes only.

References

ESC Guidelines on cardio-oncology, 2022

ACC summary of echo monitoring cadence for Anthracyclines

Cleveland Clinic review mentioning package insert cadence for anti-HER2 therapy